BIOVIE INC. - COMMON STOCK

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

19 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

26 9 2023 07:00:01 提供 Nasdaq GlobeNewswire

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

19 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

11 9 2023 07:00:01 提供 Nasdaq GlobeNewswire

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

07 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

31 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders

28 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

18 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

17 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

10 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease

26 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

23 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association

21 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

16 5 2023 15:05:00 提供 Nasdaq GlobeNewswire

BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

20 4 2023 07:30:00 提供 Nasdaq GlobeNewswire

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

17 4 2023 07:00:01 提供 Nasdaq GlobeNewswire

BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023

21 3 2023 07:01:00 提供 Nasdaq GlobeNewswire

BioVie Announces Registration Details for "BioVie Day" Webinar

14 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

13 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

09 3 2023 07:00:01 提供 Nasdaq GlobeNewswire